RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345-Reference-Cited by-同舟云学术

RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345

Published:2016-11-25 Issue:1 Volume:27 Page:1-8
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Gege Christian

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/13543776.2017.1262350

Reference23 articles.

2. Targeting Orphan Nuclear Receptors for Treatment of Metabolic Diseases and Autoimmunity

4. Targeting IL-17 and TH17 cells in chronic inflammation

5. Modulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc)

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunology of bile acids regulated receptors;Progress in Lipid Research;2024-07

2. Agonists, inverse agonists, and antagonists as therapeutic approaches to manipulate retinoic acid-related orphan receptors;Canadian Journal of Physiology and Pharmacology;2024-05-10

3. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance;Current Rheumatology Reports;2024-03-16

4. New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis;Pharmaceutics;2024-02-06

5. Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment;Journal of Inflammation Research;2024-02